29 December 2020 - Experts from the Scottish Medicines Consortium are to support a new licensing and access pathway which aims to reduce the time to market for innovative new medicines, allowing patients to benefit from them more quickly.

The Innovative Licensing and Access Pathway (ILAP), which has been developed by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allows for enhanced coordination and monitoring of product development activities by harnessing expertise from the MHRA, SMC, the National Institute for Health and Care Excellence and NHS England and NHS Improvement (NHSE&I).

Read SMC News